C4 Therapeutics to present Phase 1 biomarker data on cemsidomide plus dexamethasone in multiple myeloma trial at IMS meeting
CCCC•Meeting details
The poster is slated for the 23rd International Myeloma Society Annual Meeting in Glasgow, running September 23-26, 2026.
Positioning in multiple myeloma
The findings support cemsidomide’s positioning as a potential combination partner for immune-based therapies in multiple myeloma.
Data on cemsidomide plus dexamethasone
The data cover cemsidomide with dexamethasone, highlighting immunomodulatory effects on T cells and natural killer cells across tested once-daily doses.
Phase 1 biomarker data to be presented
C4 Therapeutics is scheduled to present new biomarker results from its Phase 1 relapsed/refractory multiple myeloma trial on September 25, 2026.
